🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to scientists.

An International Challenge

The sexually transmitted infection are on the rise around the world, with data suggesting more than 82 million infections per year. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs currently available.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Secure Clearance

Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in the same week. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a huge turning point in the management of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Data and Global Access

Based on findings released by a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which combines an injection and a pill. The research enrolled nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to register and commercialise the drug in numerous regions with limited resources.

Doctors directly involved have shared hope. Access to a one-pill regimen such as this is seen as a "revolutionary step" for gonorrhoea control. This is deemed vital to lessen the impact of the disease for people and to prevent the spread of highly drug-resistant gonorrhoea globally.